INTRODUCTION: Visceral leishmaniasis is a public health problem, with lethality reaching 10%. The recommended drug treatment is methylglucamine antimoniate. This study aimed to evaluate drug use for cases of visceral leishmaniasis treated at the Infectology Clinic of the Campo Grande University Hospital Center, State of Mato Grosso do Sul. METHODS: To collect data, we examined the medical records of 76 patients with a diagnosis of visceral leishmaniasis treated at this Infectology Clinic. RESULTS: The medical files of 76 patients (56 men and 20 women; 28.9%) showed comorbidities. The first choice drug for 88.2% of the patients was N-methylglucamine antimoniate, with a fatal outcome for 18.4%. Survival analysis showed a statistically significant difference between patients with and without comorbidities (p <0.0001) and with comorbidities who used Glucantime (p < 0.0009). The fatality rate of 18.4% indicates the low efficiency of the healthcare measures used. CONCLUSIONS: The results suggest that the prognosis becomes poor when associated with the presence of comorbidities, and that the treatment needs to be carefully administered to minimize mortality.
INTRODUCTION:Visceral leishmaniasis is a public health problem, with lethality reaching 10%. The recommended drug treatment is methylglucamine antimoniate. This study aimed to evaluate drug use for cases of visceral leishmaniasis treated at the Infectology Clinic of the Campo Grande University Hospital Center, State of Mato Grosso do Sul. METHODS: To collect data, we examined the medical records of 76 patients with a diagnosis of visceral leishmaniasis treated at this Infectology Clinic. RESULTS: The medical files of 76 patients (56 men and 20 women; 28.9%) showed comorbidities. The first choice drug for 88.2% of the patients was N-methylglucamine antimoniate, with a fatal outcome for 18.4%. Survival analysis showed a statistically significant difference between patients with and without comorbidities (p <0.0001) and with comorbidities who used Glucantime (p < 0.0009). The fatality rate of 18.4% indicates the low efficiency of the healthcare measures used. CONCLUSIONS: The results suggest that the prognosis becomes poor when associated with the presence of comorbidities, and that the treatment needs to be carefully administered to minimize mortality.
Authors: Danielle Borges Maciel; Thaís Almeida M Silva; Luciana Inácia Gomes; Edward de Oliveira; Monique Gomes Salles Tibúrcio; Rafael Faria de Oliveira; Daniel Avelar; José Ronaldo Barbosa; Eliana Furtado; Ana Rabello; Luciana de Almeida Silva Journal: Am J Trop Med Hyg Date: 2014-06-16 Impact factor: 2.345
Authors: Geraldine Madalosso; Carlos Magno Fortaleza; Ana Freitas Ribeiro; Lisete Lage Cruz; Péricles Alves Nogueira; José Angelo Lauletta Lindoso Journal: J Trop Med Date: 2012-09-13
Authors: Marcos Antônio Costa de Albuquerque; Danielle Menezes Dias; Lucas Teixeira Vieira; Carlos Anselmo Lima; Angela Maria da Silva Journal: Infect Dis Poverty Date: 2017-02-08 Impact factor: 4.520
Authors: João Gabriel Guimarães Luz; Danilo Bueno Naves; Amanda Gabriela de Carvalho; Gilvani Alves Meira; João Victor Leite Dias; Cor Jesus Fernandes Fontes Journal: Rev Inst Med Trop Sao Paulo Date: 2018-03-08 Impact factor: 1.846
Authors: Gláucia F Cota; Marcos R de Sousa; Andrea Laender Pessoa de Mendonça; Allan Patrocinio; Luiza Siqueira Assunção; Sidnei Rodrigues de Faria; Ana Rabello Journal: PLoS Negl Trop Dis Date: 2014-04-17